| Literature DB >> 26762681 |
Junya Kanda1, Ruta Brazauskas2, Zhen-Huan Hu3, Yachiyo Kuwatsuka4, Koji Nagafuji5, Heiwa Kanamori6, Yoshinobu Kanda1, Koichi Miyamura7, Makoto Murata8, Takahiro Fukuda9, Hisashi Sakamaki10, Fumihiko Kimura11, Sachiko Seo12, Mahmoud Aljurf13, Ayami Yoshimi14, Giuseppe Milone15, William A Wood16, Celalettin Ustun17, Shahrukh Hashimi18, Marcelo Pasquini3, Carmem Bonfim19, Jignesh Dalal20, Theresa Hahn21, Yoshiko Atsuta22, Wael Saber23.
Abstract
The risk of acute graft-versus-host disease (GVHD) after HLA-matched sibling bone marrow transplantation (BMT) is lower in Japanese than in Caucasian patients. However, race may have differential effect on GVHD dependent on the graft source. North American Caucasian and Japanese patients receiving their first allogeneic BMT or peripheral blood stem cell transplantation from an HLA-matched sibling for leukemia were eligible. BMT was performed in 13% of the Caucasian patients and in 53% of the Japanese patients. On multivariate analysis, the interaction term between race and graft source was not significant in any of the models, indicating that graft source does not affect the impact of race on outcomes. The risk of grade III or IV acute GVHD was significantly lower in the Japanese patients compared with the Caucasian patients (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.57 to 0.96), which resulted in lower risk of nonrelapse mortality in the Japanese patients (HR, 0.69; 95% CI, 0.54 to 0.89). The risk of relapse was also lower in this group. The lower risks of nonrelapse mortality and relapse resulted in lower overall mortality rates among the Japanese patients. In conclusion, our data indicate that irrespective of graft source, the risk of severe acute GVHD is lower in Japanese patients, resulting in a lower risk of nonrelapse mortality.Entities:
Keywords: Bone marrow transplantation; Graft-versus-host disease; Peripheral blood stem cell transplantation; Race
Mesh:
Year: 2016 PMID: 26762681 PMCID: PMC4801761 DOI: 10.1016/j.bbmt.2015.12.027
Source DB: PubMed Journal: Biol Blood Marrow Transplant ISSN: 1083-8791 Impact factor: 5.742